High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

In this report from sub-Saharan Africa, a 4-month regimen of moxifloxacin and rifapentine for pulmonary tuberculosis was not as beneficial as two 6-month regimens, and the benefits of a 6-month regimen based on rifapentine were similar to those of the standard 6-month regimen.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 371; no. 17; pp. 1599 - 1608
Main Authors:	Jindani, Amina, Harrison, Thomas S, Nunn, Andrew J, Phillips, Patrick P.J, Churchyard, Gavin J, Charalambous, Salome, Hatherill, Mark, Geldenhuys, Hennie, McIlleron, Helen M, Zvada, Simbarashe P, Mungofa, Stanley, Shah, Nasir A, Zizhou, Simukai, Magweta, Lloyd, Shepherd, James, Nyirenda, Sambayawo, van Dijk, Janneke H, Clouting, Heather E, Coleman, David, Bateson, Anna L.E, McHugh, Timothy D, Butcher, Philip D, Mitchison, Denny A
Format:	Journal Article
Language:	English
Published:	Waltham, MA Massachusetts Medical Society 23-10-2014
Subjects:	Adolescent Adult Antibiotics Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Bacterial diseases Bacterial diseases of the respiratory system Biological and medical sciences Clinical trials Coinfection Developing countries Drug Administration Schedule Drug therapy Drug Therapy, Combination Ethambutol Ethambutol - therapeutic use Female Fluoroquinolones - administration & dosage Fluoroquinolones - adverse effects General aspects HIV Seropositivity - complications Human bacterial diseases Humans Infectious diseases Isoniazid Isoniazid - therapeutic use Kaplan-Meier Estimate LDCs Male Medical sciences Middle Aged Motivation Moxifloxacin Mycobacterium tuberculosis - isolation & purification Patients Pyrazinamide Pyrazinamide - therapeutic use Rifampin Rifampin - administration & dosage Rifampin - adverse effects Rifampin - analogs & derivatives Rifampin - therapeutic use Sputum Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - complications Tuberculosis, Pulmonary - drug therapy Young Adult Botswana Lung disease Respiratory disease Pulmonary tuberculosis Mycobacterial infection Moxifloxacin Infection Medicine Fluoroquinolone derivatives Bacteriosis Antituberculous agent Antibacterial agent High dose Rifapentine Quinolone derivatives
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In this report from sub-Saharan Africa, a 4-month regimen of moxifloxacin and rifapentine for pulmonary tuberculosis was not as beneficial as two 6-month regimens, and the benefits of a 6-month regimen based on rifapentine were similar to those of the standard 6-month regimen.
Bibliography:	A complete list of the investigators in the RIFAQUIN Trial is available in the Supplementary Appendix, available at NEJM.org.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1314210